SEC Form 4/A · accession 0000899243-19-002787
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Daniel W Muehl
Officer — See Remarks
Period of report
Feb 1, 2019
Accepted (ET)
Feb 6, 2019 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $25.75 | Feb 1, 2019 | A | 29,994 | A | — | Feb 1, 2029 | Common Stock | 29,994 | 29,994 | D |
| Restricted Stock UnitsF1,F3,F4 | — | Feb 1, 2019 | A | 89,982 | A | — | — | Common Stock | 89,982 | 89,982 | D |
Explanation of responses
- F1The reporting person filed a Form 4 on February 4, 2019 that incorrectly stated (A) the number of shares of Common Stock subject to the granted option and (B) the number of Restricted Stock Units granted. This amendment to the Form 4 is being filed to correct both errors.
- F2The option shall vest as to 25% of the shares on February 1, 2020, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
- F3Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F4The Restricted Stock Units shall vest as to 25% of the units on February 1, 2020, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Executive Vice President of Finance, Principal Financial Officer and Principal Accounting Officer